WO2005090992A3 - Mptens as modifiers of the pten pathway and methods of use - Google Patents

Mptens as modifiers of the pten pathway and methods of use Download PDF

Info

Publication number
WO2005090992A3
WO2005090992A3 PCT/US2005/008222 US2005008222W WO2005090992A3 WO 2005090992 A3 WO2005090992 A3 WO 2005090992A3 US 2005008222 W US2005008222 W US 2005008222W WO 2005090992 A3 WO2005090992 A3 WO 2005090992A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
mptens
modifiers
pten
pten pathway
Prior art date
Application number
PCT/US2005/008222
Other languages
French (fr)
Other versions
WO2005090992A2 (en
Inventor
Chunyan Song
Michael Martin Ollmann
Haiguang Zhang
Lynn Margaret Bjerke
Joanne Adamkewicz
Yisheng Jin
Kim Lickteig
Original Assignee
Exelisis Inc
Chunyan Song
Michael Martin Ollmann
Haiguang Zhang
Lynn Margaret Bjerke
Joanne Adamkewicz
Yisheng Jin
Kim Lickteig
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelisis Inc, Chunyan Song, Michael Martin Ollmann, Haiguang Zhang, Lynn Margaret Bjerke, Joanne Adamkewicz, Yisheng Jin, Kim Lickteig filed Critical Exelisis Inc
Priority to AU2005258149A priority Critical patent/AU2005258149A1/en
Publication of WO2005090992A2 publication Critical patent/WO2005090992A2/en
Publication of WO2005090992A3 publication Critical patent/WO2005090992A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Human MPTEN genes are identified as modulators of the PTEN pathway, and thus are therapeutic targets for disorders associated with defective PTEN function. Methods for identifying modulators of PTEN, comprising screening for agents that modulate the activity of MPTEN are provided.
PCT/US2005/008222 2004-03-12 2005-03-10 Mptens as modifiers of the pten pathway and methods of use WO2005090992A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2005258149A AU2005258149A1 (en) 2004-06-21 2005-06-20 PGDs as modifiers of the PTEN pathway and methods of use

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US55279204P 2004-03-12 2004-03-12
US60/552,792 2004-03-12
US58168604P 2004-06-21 2004-06-21
US60/581,686 2004-06-21

Publications (2)

Publication Number Publication Date
WO2005090992A2 WO2005090992A2 (en) 2005-09-29
WO2005090992A3 true WO2005090992A3 (en) 2005-10-27

Family

ID=34994433

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/008222 WO2005090992A2 (en) 2004-03-12 2005-03-10 Mptens as modifiers of the pten pathway and methods of use

Country Status (1)

Country Link
WO (1) WO2005090992A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007020853A1 (en) 2005-08-12 2007-02-22 Astellas Pharma Inc. Method for identifying target protein of agent and method for screening therapeutic agent for diabetes using target protein
JP2009515527A (en) * 2005-11-10 2009-04-16 エクセリクシス， インク． KIFs as RHO pathway modifiers and methods of use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091699A2 (en) * 2000-05-30 2001-12-06 Advanced Research & Technology Institute Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001091699A2 (en) * 2000-05-30 2001-12-06 Advanced Research & Technology Institute Compositions and methods for identifying agents which modulate pten function and pi-3 kinase pathways
US6777439B2 (en) * 2000-05-30 2004-08-17 Advanced Research & Technology Institute, Inc. Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways
US6649359B2 (en) * 2000-06-01 2003-11-18 The Brigham & Women's Hospital, Inc. Diagnosis of endometrial precancers

Also Published As

Publication number Publication date
WO2005090992A2 (en) 2005-09-29

Similar Documents

Publication Publication Date Title
WO2005089169A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2007002131A3 (en) Galk1s as modifiers of the pten/akt pathway and methods of use
WO2006009947A3 (en) Migfs as modifiers of the igf pathway and methods of use
WO2005016287A3 (en) Prkwnks as modifiers of the rac pathway and methods of use
WO2006009928A3 (en) Galnts as modifiers of the igfr pathway and methods of use
WO2005002418A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2006036613A3 (en) Mracs as modifiers of the rac pathway and methods of use
WO2005072475A3 (en) Itpks as modifiers of the igfr pathway and methods of use
WO2005003297A3 (en) Mptens as modifiers of the pten/igf pathway and methods of use
WO2005090992A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2004024882A3 (en) FLJ20647s AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2006099183A3 (en) Nek8s as modifiers of the pten/akt pathway and methods of use
WO2005072470A3 (en) Mbms as modifiers of branching morphogenesis and methods of use
WO2005017123A3 (en) Mptens as modifiers of the pten pathway and methods of use
WO2007058860A3 (en) Mrhos as modifiers of the rho pathway and methods of use
WO2004014301A3 (en) PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE
WO2004015071A3 (en) CSNK1GS AS MODIFIERS OF THE p21 PATHWAY AND METHODS OF USE
WO2005001026A3 (en) Adks as modifiers of the pten pathway and methods of use
WO2007002081A3 (en) Gfats as modifiers of the axin pathway and methods of use
WO2004048538A3 (en) Csnks as modifiers of the rac pathway and methods of use
WO2004083389A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use
WO2005051310A3 (en) Ctpss as modifiers of the pten pathway and methods of use
WO2004048541A3 (en) Cct6s as modifiers of the rb pathway and methods of use
WO2003074725A3 (en) MBCATs AS MODIFIERS OF THE BETA-CATENIN PATHWAY AND METHODS OF USE
WO2004061123A3 (en) Mbcats as modifiers of the beta-catenin pathway and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase